ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
With the introduction of checkpoint inhibitors substantial improvements have been made in the
treatment of malignant melanoma (MM). Despite this still a a subset of patients,
approximately 50 %, experience no response to therapy.
One of the strategies to overcome these obstacles have been ACT with tumour infiltrating
lymphocytes (TILs). Most TIL based ACT products are non-specifically expanded providing
growth preference to co-infiltrated virus specific T cells, and it is currently challenging
to expand T cells in an antigen-specific manner, while at the same time obtaining the ideal
functional characteristics for specific and strong tumour-killing capacity with sufficient
persistence.
In this phase I trial artificial antigen-presenting scaffolds for antigen-driven T cell
expansion are used. These scaffolds will generate a MASE-T cell product enriched for selected
specificities towards antigens known to be expressed by melanoma cells The aim of the study
is to demonstrate that treatment with af MASE-T cell product i safe and feasible. Further the
study will elucidate whether treament with the MASE-T cell product leads to objective
responses and improves progression free survival (PFS).